Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Bellicum Pharmaceuticals (NASDAQ:BLCM) announced equity inducement grants totaling 33,000 stock options to three new employees, approved by the Board of Directors on April 30, 2022. The options have an exercise price of $1.56 per share and vest over four years, starting with 25% vesting on the first anniversary. This grant is in accordance with Nasdaq Listing Rule 5635(c)(4) and is intended to incentivize the new hires. Bellicum specializes in developing innovative cell therapies, aiming to enhance CAR-T cell effectiveness.

Positive

• Equity inducement grants of 33,000 stock options to new employees could enhance workforce motivation and retention.
• Stock options have an exercise price of $1.56, potentially favorable if the company's stock price increases.
• The company is actively expanding its workforce to support ongoing developments in therapies.

Negative

• None.

HOUSTON, May 02, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity inducement grants to 3 new employees consisting of an aggregate of 33,000 stock options. The Compensation Committee of the Board of Directors approved the grants with an effective date of April 30, 2022. The stock options were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock options have an exercise price of $1.56 per share and vest over four years, with 25% of the shares vesting on the one-year anniversary of the applicable vesting commencement date and 1/48 of the shares vesting monthly thereafter, subject to the new employee’s continued service relationship with the Company. The stock options are subject to the terms and conditions of the Company’s 2019 Equity Incentive Plan and a stock option agreement covering the grant.

About Bellicum Pharmaceuticals

Bellicum is a clinical stage biopharmaceutical company striving to deliver cures through controllable cell therapies. The company’s next-generation product candidates are differentiated by powerful cell signaling technologies designed to produce more effective CAR-T cell therapies. Bellicum’s GoCAR-T^® product candidates, BPX-601 and BPX-603, are designed to be more efficacious CAR-T cell products capable of overriding key immune inhibitory mechanisms. More information about Bellicum can be found at www.bellicum.com or follow us on Twitter or LinkedIn.

Source: Bellicum Pharmaceuticals

Investors:

Robert H. Uhl
Managing Director
Westwicke IR
858-356-5932
Robert.uhl@westwicke.com

FAQ

What is the recent stock option grant by Bellicum Pharmaceuticals (BLCM)?

Bellicum Pharmaceuticals granted 33,000 stock options to three new employees as equity inducements, with an exercise price of $1.56.

When were the stock options for BLCM employees approved?

The stock options for Bellicum Pharmaceuticals were approved on April 30, 2022.

How do the stock options at Bellicum Pharmaceuticals vest?

The stock options vest over four years, with 25% vesting on the one-year anniversary and the remainder vesting monthly.

What is the purpose of the stock option grant at Bellicum Pharmaceuticals?

The stock options were granted to incentivize new employees entering the company.